Use of systemic menopausal hormone therapy among French women: a descriptive nationwide study over the 2011 to 2024 period
- 1INSERM UMRS 1018: Centre de recherche en Epidemiologie et Sante des Populations
Abstract
BackgroundWorldwide use of systemic menopausal hormone therapy (MHT) declined sharply after 2002 following reports of increased breast cancer and cardiovascular risks. Evidence that the benefit-risk balance depends on initiation timing and treatment patterns has renewed clinical interest in MHT recently. A comprehensive characterisation of utilisation patterns is thus needed to assess alignment with guidelines. We describe systemic MHT use among women aged [≥]45 years in France between 2011 and 2024.
MethodsIn this descriptive nationwide study using the French National Health Data System (SNDS), we included 21,983,503 women aged [≥]45 years affiliated with the main health insurance scheme between 2011 and 2024. Systemic MHT was identified from reimbursements for drugs containing systemic oestrogen. Users had at least two reimbursements for systemic oestrogen (unopposed or with a progestogen) within 12 months, and initiators had no reimbursements in the preceding five years. Annual prevalence, initiation and discontinuation proportions were estimated overall and by age group.
ResultsWe identified 1,250,037 systemic MHT users and 578,668 initiators between 2011 and 2024. Annual prevalence decreased from 4.3% in 2011 to 2.0% in 2022, then stabilised, with a slight increase after 2022 among women aged 45-59 years. Prevalence was consistently highest among women aged 55-59 years. Initiation declined from 0.5% of women in 2011 to 0.2% in 2022, before increasing to 0.3% in 2024, and was highest among women aged 50-54 years. Discontinuation was highest among women aged 45-49 years, peaking in 2019, and remained stable in older age groups. Median age at initiation was 52 (Interquartile Range [IQR] 50-55) years, and median treatment duration was 2.1 (IQR 0.6-6.1) years. Most initiators (79.3%) started combined oestrogen-progestogen therapy. Oestradiol was used almost exclusively (98.5%), mainly transdermally (74.2%). Micronised progesterone was the predominant progestogen, used exclusively by 62.9% of combined therapy initiators, followed by dydrogesterone (9.2%).
ConclusionAfter prolonged declining use, systemic MHT initiation increased modestly after 2022. Prescribing appeared broadly aligned with current recommendations favouring transdermal oestradiol combined with micronised progesterone, for relatively short durations. These findings provide a benchmark for public health authorities to monitor alignment between prescribing patterns and guidelines and inform future decisions.
Related
- Patient-Centered menopause health management and menopausal hormone therapy uptake: A real-world study from a tertiary Hospital in China.
- Caregiver Experiences, Treatment Decision-Making, and Unmet Information Needs During Pediatric Growth Hormone Therapy: A Nationwide Cross-Sectional Survey in Korea.
- Menopausal status modifies the association between migraine and cardiovascular disease risk: a nationwide cohort study
- Frequency, causes, and duration of drug shortages in South Korea, 2018–2024: a nationwide descriptive analysis of regulatory reporting data and temporal patterns across the COVID-19 pandemic
- Systemic lupus erythematosus is associated with age-related macular degeneration risk in a nationwide Korean cohort
BibTeX
@misc{vilcu2026systemic,
title = {{Use of systemic menopausal hormone therapy among French women: a descriptive nationwide study over the 2011 to 2024 period}},
author = {A.-M. VILCU and P. Goussault-Capmas and Y. Zhai and M. Canonico and A. Fauconnier and J. Benichou and L. Morin and V. Viallon and A. Fournier and A. C. M. Thiebaut},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.07.26362441},
url = {https://www.medrxiv.org/content/10.64898/2026.09.07.26362441v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Use of systemic menopausal hormone therapy among French women: a descriptive nationwide study over the 2011 to 2024 period
AU - A.-M. VILCU
AU - P. Goussault-Capmas
AU - Y. Zhai
AU - M. Canonico
AU - A. Fauconnier
AU - J. Benichou
AU - L. Morin
AU - V. Viallon
AU - A. Fournier
AU - A. C. M. Thiebaut
PY - 2026
DA - 2026/09/07
PB - medRxiv
DO - 10.64898/2026.09.07.26362441
UR - https://www.medrxiv.org/content/10.64898/2026.09.07.26362441v1
AB - BackgroundWorldwide use of systemic menopausal hormone therapy (MHT) declined sharply after 2002 following reports of increased breast cancer and cardiovascular risks. Evidence that the benefit-risk balance depends on initiation timing and treatment patterns has renewed clinical interest in MHT recently. A comprehensive characterisation of utilisation patterns is thus needed to assess alignment with guidelines. We describe systemic MHT use among women aged [≥]45 years in France between 2011 and 2024. MethodsIn this descriptive nationwide study using the French National Health Data System (SNDS), we included 21,983,503 women aged [≥]45 years affiliated with the main health insurance scheme between 2011 and 2024. Systemic MHT was identified from reimbursements for drugs containing systemic oestrogen. Users had at least two reimbursements for systemic oestrogen (unopposed or with a progestogen) within 12 months, and initiators had no reimbursements in the preceding five years. Annual prevalence, initiation and discontinuation proportions were estimated overall and by age group. ResultsWe identified 1,250,037 systemic MHT users and 578,668 initiators between 2011 and 2024. Annual prevalence decreased from 4.3% in 2011 to 2.0% in 2022, then stabilised, with a slight increase after 2022 among women aged 45-59 years. Prevalence was consistently highest among women aged 55-59 years. Initiation declined from 0.5% of women in 2011 to 0.2% in 2022, before increasing to 0.3% in 2024, and was highest among women aged 50-54 years. Discontinuation was highest among women aged 45-49 years, peaking in 2019, and remained stable in older age groups. Median age at initiation was 52 (Interquartile Range [IQR] 50-55) years, and median treatment duration was 2.1 (IQR 0.6-6.1) years. Most initiators (79.3%) started combined oestrogen-progestogen therapy. Oestradiol was used almost exclusively (98.5%), mainly transdermally (74.2%). Micronised progesterone was the predominant progestogen, used exclusively by 62.9% of combined therapy initiators, followed by dydrogesterone (9.2%). ConclusionAfter prolonged declining use, systemic MHT initiation increased modestly after 2022. Prescribing appeared broadly aligned with current recommendations favouring transdermal oestradiol combined with micronised progesterone, for relatively short durations. These findings provide a benchmark for public health authorities to monitor alignment between prescribing patterns and guidelines and inform future decisions.
ER -